β-hydroxy β-methylbutyrate improves dexamethasone-induced muscle atrophy by modulating the muscle degradation pathway in SD rat

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Noh, Kyung Kyun ^a   Chung, Ki Wung ^a   Choi, Yeon Ja ^a   Park, Min Hi ^a   Jang, Eun Ji ^a   Park, Chan Hum ^a   Yoon, Changshin ^a   Kim, Nam Deuk ^a   Kim, Mi Kyung ^a   Chung, Hae Young ^a  

^a Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA HYDROXY BETA METHYLBUTYRATE; BINDING PROTEIN; BUTYRIC ACID DERIVATIVE; CREATINE KINASE; DEXAMETHASONE; LEUCINE; MUSCLE RING FINGER 1 PROTEIN; MYOD PROTEIN; PROTEIN MYHC; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; BETA-HYDROXYISOVALERIC ACID; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, RAT; GLUCOCORTICOID; MUSCLE PROTEIN; NERVE PROTEIN; TRIM63 PROTEIN, RAT; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; VALERIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOWN REGULATION; DRUG EFFECT; GASTROCNEMIUS MUSCLE; GRIP STRENGTH; IN VIVO STUDY; MUSCLE ATROPHY; MUSCLE INJURY; MUSCLE LEVEL; MUSCLE MASS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; SOLEUS MUSCLE; SUPPLEMENTATION; UBIQUITINATION; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; HAND STRENGTH; METABOLISM; MUSCLE STRENGTH; MUSCULAR ATROPHY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT;

ANIMALS; CREATINE KINASE; DEXAMETHASONE; FORKHEAD TRANSCRIPTION FACTORS; GLUCOCORTICOIDS; HAND STRENGTH; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE STRENGTH; MUSCULAR ATROPHY; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; VALERATES;

EID: 84904512054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102947     Document Type: Article

References (40)

1. Zanchi NE, Gerlinger-Romero F, Guimarães-Ferreira L, de Siqueira Filho MA, Felitti V, et al. (2011) HMB supplementation: clinical and athletic performance-related effects and mechanisms of action. Amino Acids 40: 1015-25.
2. Nissen S, Sharp R, Ray M, Rathmacher JA, Rice D, et al. (1996) Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol. 81: 2095-104. (Pubitemid 26384538)
3. Nissen SL, Abumrad NN (1997) Nutritional role of the leucine metabolite beta-hydroxy-beta-methylbutyrate (HMB). J Nutr Biochem. 8: 300-11. (Pubitemid 27325823)
4. Clark RH, Feleke G, Din M, Yasmin T, Singh G, et al. (2000) Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. J Parenter Enteral Nutr. 24: 133-9.
5. Kovarik M, Muthny T, Sispera L, Holecek (2010) Effects of β-hydroxy-β-methylbutyrate treatment in different types of skeletal muscle of intact and septic rats. J Physiol Biochem. 66: 311-9.
6. Russell ST, Tisdale MJ (2009) Mechanism of attenuation by beta-hydroxy-beta-methylbutyrate of muscle protein degradation induced by lipopolysaccharide. Mol Cell Biochem. 330: 171-9.
7. Vukovich MD, Stubbs NB, Bohlken RM (2001) Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults. J Nutr. 131: 2049-52. (Pubitemid 32661078)
8. Aversa Z, Bonetto A, Costelli P, Minero VG, Penna F, et al. (2011) β-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int J Oncol. 38: 713-20.
9. Smith HJ, Mukerji P, Tisdale MJ (2005) Attenuation of proteasome-induced proteolysis in skeletal muscle by beta-hydroxy-beta-methylbutyrate in cancer-induced muscle loss. Cancer Res. 65: 277-83. (Pubitemid 40070819)
10. Eley HL, Russell ST, Tisdale MJ (2008) Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by beta-hydroxy-beta-methylbutyrate. Am J Physiol Endocrinol Metab. 295: E1409-16.
11. Kornasio R, Riederer I, Butler-Browne G, Mouly V, Uni Z, et al. (2009) Beta-hydroxy-beta-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and survival via the MAPK/ERK and PI3K/Akt pathways. Biochim Biophys Acta. 1793: 755-63.
12. Eley HL, Russell ST, Baxter JH, Mukerji P, Tisdale MJ (2007) Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. Am J Physiol Endocrinol Metab. 293: E923-31. (Pubitemid 47535823)
13. Rhen T, Cidlowski JA (2005) Anti-inflammatory action of glucocorticoids. New mechanisms for old drugs. N. Engl. J. Med. 353: 1711-1723.
14. Hasselgren PO (1999) Glucocorticoids and muscle catabolism. Curr. Opin. Clin. Nutr. Metab. Care. 2: 201-205.
15. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294: 1704-1708. (Pubitemid 33104839)
16. Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, et al. (2007) The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6: 376-85. (Pubitemid 350011998)
17. Schakman O, Gilson H, Thiessen JP (2008) Mechanisms of glucocorticoid-induced myopathy. J. Endocrinol. 197: 1-10. (Pubitemid 351566920)
18. Foletta VC, White LJ, Larsen AE, Léger B, Russell AP (2011) The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy. Pflugers Arch - Eur J Physiol. 461: 325-335.
19. Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, et al. (2005) Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem. 280: 2847-56. (Pubitemid 40189393)
20. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, et al. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117: 399-412. (Pubitemid 38534545)
21. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, et al. (2008) The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab. 295: 785-97.
22. Daitoku H, Sakamaki J, Fukamizu A (2011) Regulation of FoxO transcriptional factors by acetylation and protein-protein interactions. Biochimica Biophysica Acta. 1813: 1954-60.
23. Van der Heide LP, Hoekmann MFM, Smidt MP (2004) The ins and outs of FoxO shuttling: mechanism of FoxO translocation and transcriptional regulation. Biochem J. 380: 297-309.
24. Aversa Z, Alamdari N, Castillero E, Muscaritoli M, Rossi Fanelli F, et al. (2012) β-Hydroxy-β-methylbutyrate (HMB) prevents dexamethasone-induced myotube atrophy. Biochem Biophys Res Commun. 423: 739-43.
25. Magal M, Dumke CL, Urbiztondo ZG, Cavill MJ, Triplett NT, et al. (2010) Relationship between serum creatine kinase activity following exercise-induced muscle damage and muscle fiber composition. J Sports Sci. 28: 257-66.
26. Lagirand-Cantaloube J, Cornille K, Csibi A, Batonnet-Pichon S, Leibovitch MP, et al. (2009) Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo. PLoS One. 4: e4973.
27. Romanick M, Thompson LV, Brown-Borg HM (2013) Murine models of atrophy, cachexia, and sarcopenia in skeletal muscle. Biochim Biophys Acta. doi:10.1016/j.bbadis.2013.03.011. [Epub ahead of print].
28. Markowitz JA, Singh P, Darras BT (2012) Spinal muscular atrophy: a clinical and research update. Pediatr Neurol. 46: 1-12.
29. Giannaki CD, Sakkas GK, Karatzaferi C, Hadjigeorgiou GM, Lavdas E, et al. (2011) Evidence of increased muscle atrophy and impaired quality of life parameters in patients with uremic restless legs syndrome. PLoS One, 6: e25180.
30. Carroll TB, Findling JW (2010) The diagnosis of Cushing's syndrome. Rev. Endocr. Metab. Disord. 11: 147-53.
31. Bowyer SL, La Mothe MP, Hollister JR (1985) Steroid myopathy: incidence and detection in a population with asthma. J. Allergy Clin. Immunol. 76: 234-42. (Pubitemid 15003566)
32. Glass DJ (2003) Signalling pathways that mediates skeletal muscle hypertrophy and atrophy. Nat. Cell. Biol. 5: 87-90.
33. Bonaldo P, Sandri M (2013) Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech. 6: 25-39.
34. Kim JS, Wilson JM, Lee SR (2010) Dietary implications on mechanisms of sarcopenia: roles of protein, amino acids and antioxidants. J. Nutr. Biochem. 21: 1-13.
35. Vazeille E, Slimani L, Claustre A, Magne H, Labas R, et al. (2012) Curcumin treatment prevents increased proteasome and apoptosome activities in rat skeletal muscle during reloading and improves subsequent recovery. J. Nutr. Biochem. 23: 245-51.
36. Marcora S, Lemmey A, Maddison P (2005) Dietary treatment of rheumatoid cachexia with beta-hydroxy-beta-methylbutyrate, glutamine and arginine: a randomised controlled trial. Clin. Nutr. 24: 442-54. (Pubitemid 40668432)
37. Yamamoto D, Maki T, Herningtyas EH, Ikeshita N, Shibahara H, et al. (2010) Branched-chain amino acids protect against dexamethasone-induced soleus muscle atrophy in rats. Muscle Nerve. 41: 819-27.
38. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, et al. (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 14: 395-403. (Pubitemid 38591410)
39. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96: 857-68. (Pubitemid 29165088)
40. Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA (1996) MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev. 10: 1173-83. (Pubitemid 26171100)